esmolol   Click here for help

GtoPdb Ligand ID: 7178

Synonyms: Brevibloc® | SL-8052
Approved drug
esmolol is an approved drug (FDA (1986))
Compound class: Synthetic organic
Comment: Esmolol is a β-blocker.
Marketed formulations may contain esmolol hydrochloride (PubChem CID 104769).
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 4
Hydrogen bond donors 2
Rotatable bonds 10
Topological polar surface area 67.79
Molecular weight 295.18
XLogP 1.68
No. Lipinski's rules broken 0

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)

SMILES / InChI / InChIKey
Click here for help
Canonical SMILES COC(=O)CCc1ccc(cc1)OCC(CNC(C)C)O
Isomeric SMILES COC(=O)CCc1ccc(cc1)OCC(CNC(C)C)O
InChI InChI=1S/C16H25NO4/c1-12(2)17-10-14(18)11-21-15-7-4-13(5-8-15)6-9-16(19)20-3/h4-5,7-8,12,14,17-18H,6,9-11H2,1-3H3
InChI Key AQNDDEOPVVGCPG-UHFFFAOYSA-N

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)

References
1. Baker JG, Fromont C, Bruder M, Thompson KSJ, Kellam B, Hill SJ, Gardiner SM, Fischer PM. (2020)
Using Esterase Selectivity to Determine the In Vivo Duration of Systemic Availability and Abolish Systemic Side Effects of Topical β-Blockers.
ACS Pharmacol Transl Sci, 3 (4): 737-748. [PMID:32832874]
2. Lim VJY, Proudman RGW, Monteleone S, Kolb P, Baker JG. (2023)
The Isoleucine at Position 118 in Transmembrane 2 Is Responsible for the Selectivity of Xamoterol, Nebivolol, and ICI89406 for the Human β1-Adrenoceptor.
Mol Pharmacol, 103 (2): 89-99. [PMID:36351797]
3. Nasrollahi-Shirazi S, Sucic S, Yang Q, Freissmuth M, Nanoff C. (2016)
Comparison of the β-Adrenergic Receptor Antagonists Landiolol and Esmolol: Receptor Selectivity, Partial Agonism, and Pharmacochaperoning Actions.
J Pharmacol Exp Ther, 359 (1): 73-81. [PMID:27451411]